Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I.

Lancet Diabetes Endocrinol. 2019 Jun 10. pii: S2213-8587(19)30180-9. doi: 10.1016/S2213-8587(19)30180-9. [Epub ahead of print]

PMID:
31196815
2.

Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals.

Wilson R, Templeton A, Leemereise C, Eames R, Banham-Hall E, Hessel EM, Cahn A.

Clin Ther. 2019 Jun;41(6):1214-1220. doi: 10.1016/j.clinthera.2019.04.008. Epub 2019 May 7.

PMID:
31076203
3.

Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53.

Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BM.

Clin Chem. 2019 Jun;65(6):781-790. doi: 10.1373/clinchem.2018.298489. Epub 2019 Apr 15.

PMID:
30988169
4.

Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase δ Inhibitor.

Begg M, Edwards CD, Hamblin JN, Pefani E, Wilson R, Gilbert J, Vitulli G, Mallett D, Morrell J, Hingle MI, Uddin S, Ehtesham F, Marotti M, Harrell A, Newman CF, Fernando D, Clark J, Cahn A, Hessel EM.

J Pharmacol Exp Ther. 2019 Jun;369(3):443-453. doi: 10.1124/jpet.119.257311. Epub 2019 Apr 2.

PMID:
30940692
5.

Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib.

Begg M, Wilson R, Hamblin JN, Montembault M, Green J, Deans A, Amour A, Worsley S, Fantom K, Cui Y, Dear G, Ahmad S, Kielkowska A, Clark J, Boyce M, Cahn A, Hessel EM.

J Pharmacol Exp Ther. 2019 Jun;369(3):337-344. doi: 10.1124/jpet.118.255109. Epub 2019 Mar 18.

PMID:
30886125
6.

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.

Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD.

Circulation. 2019 May 28;139(22):2516-2527. doi: 10.1161/CIRCULATIONAHA.119.039996. Epub 2019 Mar 18.

PMID:
30882239
7.

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.

Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD.

Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18.

PMID:
30882238
8.

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.

Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.

PMID:
30786725
9.

Use of autologous 99mTechnetium-labelled neutrophils to quantify lung neutrophil clearance in COPD.

Tregay N, Begg M, Cahn A, Farahi N, Povey K, Madhavan S, Simmonds R, Gillett D, Solanki C, Wong A, Maison J, Lennon M, Bradley G, Jarvis E, de Groot M, Wilson F, Babar J, Peters AM, Hessel EM, Chilvers ER.

Thorax. 2019 Jul;74(7):659-666. doi: 10.1136/thoraxjnl-2018-212509. Epub 2019 Jan 23.

10.

Clinical and Molecular Characteristics of Eight Israeli Families with Thyroid Hormone Receptor Beta Mutations.

Zaig E, Cohen-Ouaknine O, Tsur A, Nagar S, Bril G, Tolkin L, Cahn A, Heyman M, Glaser B.

Isr Med Assoc J. 2018 Nov;20(11):679-686.

11.

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.

Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.

PMID:
30424892
12.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators.

N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.

PMID:
30415602
13.

Validity of diagnostic codes and estimation of prevalence of diabetic foot ulcers using a large electronic medical record database.

Cahn A, Altaras T, Agami T, Liran O, Touaty CE, Drahy M, Pollack R, Raz I, Chodick G, Zucker I.

Diabetes Metab Res Rev. 2019 Feb;35(2):e3094. doi: 10.1002/dmrr.3094. Epub 2018 Nov 20.

PMID:
30378240
14.

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.

Yale JF, Aroda VR, Charbonnel B, Sinclair AJ, Trescoli C, Cahn A, Bigot G, Merino-Trigo A, Brulle-Wohlhueter C, Bolli GB, Ritzel R.

Diabetes Metab. 2018 Oct 23. pii: S1262-3636(18)30196-4. doi: 10.1016/j.diabet.2018.10.002. [Epub ahead of print]

15.

Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese Subjects.

Ino H, Wilson R, Terao T, Ogura H, Igarashi H, Cahn A, Numachi Y.

Clin Pharmacol Drug Dev. 2019 Jan;8(1):78-86. doi: 10.1002/cpdd.614. Epub 2018 Oct 10.

PMID:
30303626
16.

A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.

Khindri S, Cahn A, Begg M, Montembault M, Leemereise C, Cui Y, Hogg A, Wajdner H, Yang S, Robertson J, Hamblin JN, Ludwig-Sengpiel A, Kornmann O, Hessel EM.

J Pharmacol Exp Ther. 2018 Dec;367(3):405-413. doi: 10.1124/jpet.118.249516. Epub 2018 Sep 14.

PMID:
30217958
17.

Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.

Cahn A, Melzer-Cohen C, Pollack R, Chodick G, Shalev V.

Diabetes Obes Metab. 2019 Feb;21(2):340-348. doi: 10.1111/dom.13532. Epub 2018 Oct 15.

PMID:
30207040
18.

Comparison of HBA1c Goals Proposed by an Algorithm To Those Set By Different Members of Healthcare Teams Within the Dartmouth Hitchcock Health System.

Delgado-Hurtado JJ, Cahn A, Raz I, Comi RJ.

Endocr Pract. 2018 Aug;24(8):705-709. doi: 10.4158/EP-2018-0102.

PMID:
30183396
19.

Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.

Wilson R, Jarvis E, Montembault M, Hamblin JN, Hessel EM, Cahn A.

Clin Ther. 2018 Aug;40(8):1410-1417. doi: 10.1016/j.clinthera.2018.06.011. Epub 2018 Jul 25.

PMID:
30055824
20.

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS.

Am Heart J. 2018 Jun;200:83-89. doi: 10.1016/j.ahj.2018.01.012. Epub 2018 Feb 7.

PMID:
29898853
21.

Functional respiratory imaging: heterogeneity of acute exacerbations of COPD.

van Geffen WH, Hajian B, Vos W, De Backer J, Cahn A, Usmani OS, Van Holsbeke C, Pistolesi M, Kerstjens HA, De Backer W.

Int J Chron Obstruct Pulmon Dis. 2018 May 30;13:1783-1792. doi: 10.2147/COPD.S152463. eCollection 2018.

22.

Low thyroid-stimulating hormone and its persistence beyond the first trimester of pregnancy.

Fraenkel M, Shafat T, Cahn A, Erez O, Novack V, Tsur A.

Int J Gynaecol Obstet. 2018 Sep;142(3):270-276. doi: 10.1002/ijgo.12540. Epub 2018 Jun 22.

PMID:
29856070
23.

Global status of diabetes prevention and prospects for action: A consensus statement.

Ibrahim M, Tuomilehto J, Aschner P, Beseler L, Cahn A, Eckel RH, Fischl AH, Guthrie G, Hill JO, Kumwenda M, Leslie RD, Olson DE, Pozzilli P, Weber SL, Umpierrez GE.

Diabetes Metab Res Rev. 2018 Sep;34(6):e3021. doi: 10.1002/dmrr.3021. Epub 2018 Jun 8. Review.

PMID:
29757486
24.

The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.

Hammond M, Clark AB, Cahn AP, Chilvers ER, Fraser WD, Livermore DM, Maher TM, Parfrey H, Swart AM, Stirling S, Thickett D, Whyte M, Wilson A.

Trials. 2018 Feb 5;19(1):89. doi: 10.1186/s13063-018-2453-6.

25.

Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.

Bergmark BA, Scirica BM, Steg PG, Fanola CL, Gurmu Y, Mosenzon O, Cahn A, Raz I, Bhatt DL; SAVOR-TIMI 53 Investigators.

Eur Heart J. 2018 Jun 21;39(24):2255-2262. doi: 10.1093/eurheartj/ehx809.

26.

DECLARE-TIMI 58: Participants' baseline characteristics.

Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Johansson PA, Sabatine MS, Wiviott SD.

Diabetes Obes Metab. 2018 May;20(5):1102-1110. doi: 10.1111/dom.13217. Epub 2018 Feb 14.

PMID:
29322605
27.

Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real-life clinical practice.

Alvarez-Guisasola F, Cebrián-Cuenca AM, Cos X, Ruiz-Quintero M, Millaruelo JM, Cahn A, Raz I, Orozco-Beltrán D; Spanish Society of Family Medicine Diabetes Group.

Diabetes Metab Res Rev. 2018 Mar;34(3). doi: 10.1002/dmrr.2976. Epub 2018 Jan 24.

PMID:
29271560
28.

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease.

Bergmark BA, Bhatt DL, Braunwald E, Morrow DA, Steg PG, Gurmu Y, Cahn A, Mosenzon O, Raz I, Bohula E, Scirica BM.

Diabetes Care. 2018 Mar;41(3):577-585. doi: 10.2337/dc17-1736. Epub 2017 Dec 1.

29.

Digital health technology and diabetes management.

Cahn A, Akirov A, Raz I.

J Diabetes. 2018 Jan;10(1):10-17. doi: 10.1111/1753-0407.12606. Epub 2017 Nov 6. Review.

PMID:
28872765
30.

Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.

Cahn A, Hamblin JN, Begg M, Wilson R, Dunsire L, Sriskantharajah S, Montembault M, Leemereise CN, Galinanes-Garcia L, Watz H, Kirsten AM, Fuhr R, Hessel EM.

Pulm Pharmacol Ther. 2017 Oct;46:69-77. doi: 10.1016/j.pupt.2017.08.008. Epub 2017 Aug 17.

31.

Incorporation of a Stress Reducing Mobile App in the Care of Patients With Type 2 Diabetes: A Prospective Study.

Munster-Segev M, Fuerst O, Kaplan SA, Cahn A.

JMIR Mhealth Uhealth. 2017 May 29;5(5):e75. doi: 10.2196/mhealth.7408.

32.

Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.

Cernea S, Cahn A, Raz I.

Expert Rev Clin Pharmacol. 2017 May;10(5):535-547. doi: 10.1080/17512433.2017.1300059. Epub 2017 Mar 6. Review.

PMID:
28276774
33.

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study.

Cahn A, Mosenzon O, Bhatt DL, Leibowitz G, Yanuv I, Rozenberg A, Iqbal N, Hirshberg B, Stahre C, Im K, Kanevsky E, Raz I.

Diabetes Obes Metab. 2017 Jul;19(7):1045-1050. doi: 10.1111/dom.12903. Epub 2017 Mar 8.

PMID:
28181728
34.

Continuous subcutaneous insulin infusion-an opportunity for better care but not a "magic pill".

Cahn A, Roitman E, Aharon-Hananel G, Raz I.

Endocrine. 2017 Apr;56(1):4-6. doi: 10.1007/s12020-016-1217-x. Epub 2016 Dec 30. No abstract available.

PMID:
28039560
35.
36.

An update on DPP-4 inhibitors in the management of type 2 diabetes.

Cahn A, Cernea S, Raz I.

Expert Opin Emerg Drugs. 2016 Dec;21(4):409-419. Epub 2016 Nov 18. Review.

PMID:
27809608
37.

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.

Mosenzon O, Leibowitz G, Bhatt DL, Cahn A, Hirshberg B, Wei C, Im K, Rozenberg A, Yanuv I, Stahre C, Ray KK, Iqbal N, Braunwald E, Scirica BM, Raz I.

Diabetes Care. 2017 Jan;40(1):69-76. doi: 10.2337/dc16-0621. Epub 2016 Oct 17.

38.

Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes.

Kochba E, Levin Y, Raz I, Cahn A.

Diabetes Technol Ther. 2016 Sep;18(9):525-31. doi: 10.1089/dia.2016.0156. Epub 2016 Aug 8.

39.

Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.

Schernthaner G, Cahn A, Raz I.

Diabetes Care. 2016 Aug;39 Suppl 2:S210-8. doi: 10.2337/dcS15-3009. No abstract available.

PMID:
27440835
40.

Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes.

Cahn A, Cefalu WT.

Diabetes Care. 2016 Aug;39 Suppl 2:S137-45. doi: 10.2337/dcS15-3007.

41.

Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial.

Cahn A, Raz I, Mosenzon O, Leibowitz G, Yanuv I, Rozenberg A, Iqbal N, Hirshberg B, Sjostrand M, Stahre C, Im K, Kanevsky E, Scirica BM, Bhatt DL, Braunwald E.

Diabetes Care. 2016 Aug;39(8):1329-37. doi: 10.2337/dc15-2763. Epub 2016 May 23.

PMID:
27222508
42.

The role of insulin pump therapy for type 2 diabetes mellitus.

Landau Z, Raz I, Wainstein J, Bar-Dayan Y, Cahn A.

Diabetes Metab Res Rev. 2017 Jan;33(1). doi: 10.1002/dmrr.2822. Epub 2016 Jun 21. Review.

PMID:
27189155
43.

Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.

Cahn A, Cernea S, Raz I.

Rev Endocr Metab Disord. 2016 Mar;17(1):117-27. doi: 10.1007/s11154-016-9351-6. Review.

PMID:
27106831
44.

Heart failure: SGLT2 inhibitors and heart failure -- clinical implications.

Raz I, Cahn A.

Nat Rev Cardiol. 2016 Apr;13(4):185-6. doi: 10.1038/nrcardio.2016.35. Epub 2016 Mar 10.

PMID:
26961066
45.

Saxagliptin for the treatment of diabetes - a focus on safety.

Cernea S, Cahn A, Raz I.

Expert Opin Drug Saf. 2016 May;15(5):697-707. doi: 10.1517/14740338.2016.1159675. Epub 2016 Mar 21. Review.

PMID:
26923222
46.

Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c.

Cavender MA, Scirica BM, Raz I, Steg PG, McGuire DK, Leiter LA, Hirshberg B, Davidson J, Cahn A, Mosenzon O, Im K, Braunwald E, Bhatt DL.

Am J Med. 2016 Mar;129(3):340.e1-8. doi: 10.1016/j.amjmed.2015.09.022. Epub 2015 Oct 31.

PMID:
26524706
47.

Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists.

Cahn A, Raz I, Kleinman Y, Balicer R, Hoshen M, Lieberman N, Brenig N, Del Prato S, Cefalu WT.

Diabetes Care. 2015 Dec;38(12):2293-300. doi: 10.2337/dc15-0187. Epub 2015 Oct 30.

48.

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.

Leiter LA, Teoh H, Mosenzon O, Cahn A, Hirshberg B, Stahre CA, Hoekstra JB, Alvarsson M, Im K, Scirica BM, Bhatt DL, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.

Diabetes Obes Metab. 2016 Feb;18(2):186-90. doi: 10.1111/dom.12582. Epub 2015 Nov 27.

PMID:
26443993
49.

Response to: 'Baseline differences in SAVOR trial'-- prespecified vs. post hoc analysis--a potential source of bias.

Raz I, Cahn A, Mosenzon O, Scirica BM, Bhatt DL.

Diabetes Obes Metab. 2015 Dec;17(12):1203-4. doi: 10.1111/dom.12579. No abstract available.

PMID:
26419822
50.

Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.

Prime D, de Backer W, Hamilton M, Cahn A, Preece A, Kelleher D, Baines A, Moore A, Brealey N, Moynihan J.

J Aerosol Med Pulm Drug Deliv. 2015 Dec;28(6):486-97. doi: 10.1089/jamp.2015.1224. Epub 2015 Sep 15.

Supplemental Content

Support Center